Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Moderna, Inc.NASDAQ: MRNA

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax turns positive

Q3 FY2026 income before tax was $171M, compared with -$187M a year earlier. Trailing-twelve-month income before tax was -$2.73B.

Context

  • Income before tax amounted to 142.4% of revenue in FY2025, up 29.6 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near $171M or moves back toward the trailing-twelve-month quarterly average of -$682.25M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$171M+122.3% QoQ
Last fiscal yearDec 2025
-$2.77B+23.3% YoY
LTMSep 2026
-$2.73B+13.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+191.4%——
1 year+23.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(2.77B) USD
Year-over-year change
+23.3%

Income Before Tax vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.4% is the 3rd highest of 10, against a peer median of -60.0%.
  • Income before tax amounts to 108.1% of revenue for MRNA, versus a peer median of 61.9%.
MRNA Competitors
Income Before Tax for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GSKGSK plcLTM Jun 2026£5.9B GBP+27.7%+9.6%17.8%
PFEPfizer Inc.LTM Jun 2026$4.21B USD-60.0%-40.0%6.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$78.67M USD-14.7%—173.5%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$84.93M USD+12.0%——
NVAXNovavax, Inc.LTM Mar 2026-$86.19M USD-117.6%—14.5%
VALNValneva SELTM Mar 2026-€137.61M EUR-76.1%—88.0%
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.35M USD+23.6%—675.4%
PCVXVaxcyte, Inc.LTM Jun 2026-$1.06B USD-94.4%——
BNTXBioNTech SELTM Jun 2026-€1.64B EUR-321.6%—61.9%
MRNAModerna, Inc.LTM Sep 2026-$2.73B USD+13.4%—108.1%
Peer median (excluding MRNA) —-60.0%-15.2%61.9%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.